JP2023540795A5 - - Google Patents
Info
- Publication number
- JP2023540795A5 JP2023540795A5 JP2023516052A JP2023516052A JP2023540795A5 JP 2023540795 A5 JP2023540795 A5 JP 2023540795A5 JP 2023516052 A JP2023516052 A JP 2023516052A JP 2023516052 A JP2023516052 A JP 2023516052A JP 2023540795 A5 JP2023540795 A5 JP 2023540795A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- pharmaceutical composition
- treatment
- composition according
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078211P | 2020-09-14 | 2020-09-14 | |
| US63/078,211 | 2020-09-14 | ||
| US202063106302P | 2020-10-27 | 2020-10-27 | |
| US63/106,302 | 2020-10-27 | ||
| US202163185357P | 2021-05-06 | 2021-05-06 | |
| US63/185,357 | 2021-05-06 | ||
| PCT/IB2021/058229 WO2022053990A1 (en) | 2020-09-14 | 2021-09-10 | Methods, therapies and uses for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540795A JP2023540795A (ja) | 2023-09-26 |
| JP2023540795A5 true JP2023540795A5 (https=) | 2024-09-17 |
Family
ID=77989848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516052A Pending JP2023540795A (ja) | 2020-09-14 | 2021-09-10 | がんを処置するための方法、治療、および使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230340137A1 (https=) |
| EP (1) | EP4211167A1 (https=) |
| JP (1) | JP2023540795A (https=) |
| KR (1) | KR20230069181A (https=) |
| CN (1) | CN116194105A (https=) |
| AU (2) | AU2021339096B2 (https=) |
| BR (1) | BR112023003688A2 (https=) |
| CA (1) | CA3194925A1 (https=) |
| IL (1) | IL300884A (https=) |
| MX (1) | MX2023003034A (https=) |
| WO (1) | WO2022053990A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250116736A (ko) * | 2022-12-09 | 2025-08-01 | 화이자 인코포레이티드 | Cd47 차단제 및 항-bcma/항-cd3 이중특이성 항체 병용 요법 |
| EP4731255A1 (en) * | 2023-06-22 | 2026-04-29 | Genentech, Inc. | Treatment of multiple myeloma |
| TW202523350A (zh) | 2023-08-10 | 2025-06-16 | 美商輝瑞股份有限公司 | 治療癌症之方法，療法及用途 |
| WO2025096717A1 (en) * | 2023-11-01 | 2025-05-08 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
| WO2025122813A1 (en) * | 2023-12-08 | 2025-06-12 | Board Of Regents, The University Of Texas System | Protecting cell therapies from tgf-beta induced immunosuppression |
| TW202532072A (zh) * | 2023-12-08 | 2025-08-16 | 美商西建公司 | 治療多發性骨髓瘤之療法 |
| WO2026059920A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| DK1730119T3 (da) | 2004-03-23 | 2008-08-11 | Pfizer Prod Inc | Imidazolforbindelser til behandling af neurodegenerative forstyrrelser |
| PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| CN104185477B (zh) | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
| WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| TWI703159B (zh) * | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| MX2018002043A (es) * | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| IL313608A (en) * | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| JP7267914B2 (ja) * | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| US20200179511A1 (en) * | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
| MY201312A (en) | 2017-06-02 | 2024-02-16 | Pfizer | Antibodies specific for flt3 and their uses |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| CA3105729A1 (en) * | 2018-07-31 | 2020-02-06 | Amgen Research (Munich) Gmbh | Dosing regimen for bcma-cd3 bispecific antibodies |
| CA3110513A1 (en) * | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| US20220003772A1 (en) * | 2018-10-31 | 2022-01-06 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| BR112022021956A2 (pt) * | 2020-05-13 | 2022-12-13 | Pfizer | Métodos, terapias e usos para o tratamento de câncer |
-
2021
- 2021-09-10 WO PCT/IB2021/058229 patent/WO2022053990A1/en not_active Ceased
- 2021-09-10 AU AU2021339096A patent/AU2021339096B2/en active Active
- 2021-09-10 MX MX2023003034A patent/MX2023003034A/es unknown
- 2021-09-10 EP EP21782599.1A patent/EP4211167A1/en active Pending
- 2021-09-10 US US18/025,879 patent/US20230340137A1/en active Pending
- 2021-09-10 IL IL300884A patent/IL300884A/en unknown
- 2021-09-10 CN CN202180062823.5A patent/CN116194105A/zh active Pending
- 2021-09-10 JP JP2023516052A patent/JP2023540795A/ja active Pending
- 2021-09-10 BR BR112023003688A patent/BR112023003688A2/pt unknown
- 2021-09-10 KR KR1020237012640A patent/KR20230069181A/ko active Pending
- 2021-09-10 CA CA3194925A patent/CA3194925A1/en active Pending
-
2026
- 2026-03-11 AU AU2026201847A patent/AU2026201847A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023540795A5 (https=) | ||
| JP2018506550A5 (https=) | ||
| JP2020519295A5 (https=) | ||
| JP2017523187A5 (https=) | ||
| JP2019517549A5 (https=) | ||
| JP2018184417A5 (https=) | ||
| JP2021517566A5 (https=) | ||
| JP2019521988A5 (https=) | ||
| JP2023501375A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2022189827A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2015525798A5 (https=) | ||
| JP2014511383A5 (https=) | ||
| JP2019501886A5 (https=) | ||
| JP2018530578A5 (https=) | ||
| JP2015517511A5 (https=) | ||
| RU2014127298A (ru) | Применения иммуноконъюгатов, мишенью которых является cd138 | |
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| RU2017128616A (ru) | Комбинированное лекарственное средство | |
| JP2015172060A5 (https=) | ||
| RU2020134307A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| JP2020158544A5 (https=) | ||
| JP2017537927A5 (https=) | ||
| JP2025515092A5 (https=) | ||
| JP2019519584A5 (https=) |